Lightnews — Scholar-powered news

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 50m

✨#ESMO25✨

🚨BREAKING: KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma

📈 Durable Benefit: 5-year OS results in the pMMR subgroup are consistent with the overall population.

💡 Improved Outcomes: OS rate of 19.9% with KEYTRUDA + LENVIMA vs. 7.7% with chemotherapy.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1h

✨#ESMO25✨

🚨BREAKING: PADCEV™(enfortumab vedotin) + KEYTRUDA™(pembrolizumab) in MIBC

➡️ First and only perioperative combo to improve survival in cisplatin-ineligible patients.

📊 Phase 3 EV-303 trial shows 60% lower risk of recurrence or progression and 50% improvement in overall outcomes.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 3h

#ONCOnews #OncoAlert #OncEd #ESMO2025 #Oncology #Melanoma #Immunotherapy #CancerResearch

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 3h

✨#ESMO25✨

🚨BREAKING: 9-Year CheckMate 238 Results!

🩸 Nivolumab shows longer recurrence-free survival vs. ipilimumab in patients with resected stage III/IV melanoma.

⏳ First long-term data highlight durable benefits of immunotherapy in melanoma.

🔗 Read more: bit.ly/ONCOnews19O-5

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 4h

✨#ESMO25✨

🚨 BREAKING: DESTINY-Breast05 Phase III Results!

🎗️ Enhertu (trastuzumab deruxtecan) reduced the risk of recurrence or death by 53% vs. T-DM1 in high-risk HER2+ early breast cancer after neoadjuvant therapy.

🌟 Over 92% of patients on Enhertu remained free of invasive disease at 3 years.

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 5h

#ONCOnews #OncoAlert #OncEd #ESMO2025 #Oncology #NSCLC
#LungCancer #CancerResearch

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 5h

✨#ESMO25✨

🚨 BREAKING: MARIPOSA Trial – Final OS Results!

💊 Rybrevant (amivantamab) – lazertinib shows promise in EGFR-mutated advanced NSCLC as first-line therapy.

✅ Approved by the European Medicines Agency for advanced NSCLC.

🔗 Read more: bit.ly/ONCOnews19O-3

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8h

#ONCOnews #OncoAlert #OncEd #ESMO2025 #Oncology #OvarianCancer #PrecisionOncology

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8h

✨#ESMO25✨

🚨BREAKING: EPIK-O/ENGOT-ov61 Trial Update!

💊 Alpelisib + Olaparib vs Chemotherapy in platinum-resistant/refractory high-grade serous ovarian cancer (HGSOC) without BRCA mutation

🌟 Highlighting new insights for patients with limited treatment options.

🔗 Read more: bit.ly/ONCOnews19O-2

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 9h

✨#ESMO25✨

🚨BREAKING: VIKTORIA-1 Phase 3 Update!

🧬 The PIK3CA-mutant cohort in the Phase 3 VIKTORIA-1 trial is now fully enrolled.

📈 Phase 1b data show a median PFS of 14.6 months with gedatolisib + fulvestrant + palbociclib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 23h

✨ Day 2 at #ESMO2025 was all about exciting conversations and great energy.

We’re thrilled to meet so many oncology professionals — join us again on Day 3! 🤝

#ONCOnews #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO25 #Berlin #Germany

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

#ONCOnews #OncoAlert #OncEd#NSCLC #LungCancer #Oncology #ClinicalTrials #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: Zongertinib in Advanced HER2-Mutant NSCLC

🎯 Boehringer’s zongertinib showed a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC in the Phase Ib Beamion LUNG-1 trial at #ESMO25.

🔗 Read more: bit.ly/ONCOnews18O-4

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: AMPLITUDE Trial Updates!

📊 Patient-reported outcomes from the AMPLITUDE trial evaluating Niraparib + Abiraterone Acetate + Prednisone in metastatic hormone-sensitive prostate cancer (mHSPC) patients with homologous recombination repair (HRR) mutations.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #ClinicalTrials #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: Sevabertinib in Advanced HER2-Mutant NSCLC.

➡️ HER2 mutations occur in 2–4% of NSCLC patients.

💊 Sevabertinib, an oral reversible tyrosine kinase inhibitor, shows promising anti-HER2 activity in preclinical models.

🔗 Read more: bit.ly/ONCOnews18O-2

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

#ONCOnews #OncoAlert #OncEd #LungCancer #Phase3Data #OncologyNews #ESMO2025

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: Phase 3 Data!

📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.

✅ Reinforces its potential as a new first-line standard of care.

🔗 Read more: bit.ly/ONCOnews18O-1

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 1d

✨#ESMO25✨

🚨BREAKING: POTOMAC Phase 3 Update!
➡️ 32% lower risk of disease recurrence or death in high-risk non–muscle-invasive bladder cancer with Imfinzi(durvalumab) vs. BCG alone.
⏱️ 1year of Imfinzi added to BCG induction and maintenance delivered early and sustained disease-free survival benefit.

1 1